Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 11/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21681604 | 0.91 | KDM4E (0.49) | KDM4EALDH1A1HPGDRAB9AMAPK10 | |
| SCHEMBL20075837 | 0.85 | KDM4E (0.36) | KDM4EALDH1A1HPGDRAB9AMAPK10 | |
| SCHEMBL12290303 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1HPGDRAB9AMAPK10 | |
| SCHEMBL20075885 | 0.78 | HAVCR2 (0.32) | KDM4EALDH1A1HPGDRAB9AMAPK10 | |
| SCHEMBL9143661 | 0.78 | KDM4E (0.38) | KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL20075890 | 0.76 | NPY5R (0.38) | KDM4EALDH1A1HPGDRAB9AMAPK10 | |
| SCHEMBL26662250 | 0.75 | KDM4E (0.48) | KDM4EALDH1A1HPGDRAB9AMAPK10 | |
| SCHEMBL20588719 | 0.75 | KDM4E (0.44) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL20075842 | 0.74 | NPC1 (0.50) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL30217893 | 0.73 | KDM4E (0.46) | KDM4EALDH1A1HPGDRAB9AMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048259-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | US | claimed |
| US-20200048259-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048259-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-13 | — | — | US | disclosed |
| WO-2018071282-A1 | KDM5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048259-A1 | KDM5 INHIBITORS | KDM5A, KDM5B, KDM5C | KDM4E 11/4885ALDH1A1 1410/4885HPGD 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.